High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b.
Fan-Pu JiJie LiLi LiuJing LiangXiaozhong WangJunping LiuDachuan CaiRui HuangJiajie ZhangQi WangYuemin NanJunyi LiQing YeMingyuan ZhangQiang XuFeng GuoChangqing ZhaoLingdi LiuCaini HeYu LiWenjun WangLeslie Y KamSally TranMayumi MaedaAkiko MizutaZongfang LiShuangsuo DangWanhua RenQiang ZhuRamsey CheungJunqi NiuWen XieHongying PanHong RenChao WuJia ShangFengmei WangMindie H NguyenPublished in: Journal of gastroenterology and hepatology (2020)
In real-world Chinese patients with diverse GTs, Chinese Food and Drug Administration-approved interferon-free DAAs were well tolerated, provided high cure rates (98.0% overall) including GT3a/3b, and led to improvement of liver function.